CYT-101 is under clinical development by Cyteph and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CYT-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CYT-101 overview
CYT-101 is under development for the treatment of primary and recurrent glioblastoma multiforme and astrocytoma. The therapeutic candidate comprises off-the-shelf, human leukocyte antigen (HLA)-matched cytomegalovirus (CMV)-specific T cells. It is being developed based on CAR T delivery platform Cyt-ATTAC (Cytomegalovirus – Allogeneicu Tumor Targeting Car T). It is administered through parenteral route.
Cyteph overview
Cyteph is a biotechnology company that focuses on developing T cell and CAR T cell therapies to target and destroy solid tumors. The company is headquartered in Herston, Queensland, Australia.
For a complete picture of CYT-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
